688331 Remegen Co.,Ltd.
Closed 12-23 15:00:00
80.10
+0.19
+0.24%
High81.36Low79.71Vol3.99M
Open80.00D1 Closing79.91Amplitude2.06%
Mkt Cap45.18BTradable Cap12.98BTotal Shares564.00M
T/O321.00MT/O Rate2.46%Tradable Shares162.00M
P/B19.46ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

HK Stock Movement | REMEGEN (09995) Rises Over 3% as Self-Developed RC148 Achieves Dual-Path Breakthrough; Institutions Bullish on Clinical Potential
Stock News  ·  10:06
HK Stock Movement | REMEGEN (09995) Rises Over 3% as Self-Developed RC148 Achieves Dual-Path Breakthrough; Institutions Bullish on Clinical Potential
RemeGen Board Approves A Share Repurchase Plan to Support Employee Incentives
Reuters  ·  12-15
RemeGen Board Approves A Share Repurchase Plan to Support Employee Incentives
Remegen Co.,Ltd. (688331.SH) Plans to Repurchase Shares Worth 20-40 Million Yuan
Stock News  ·  12-15
Remegen Co.,Ltd. (688331.SH) Plans to Repurchase Shares Worth 20-40 Million Yuan
HK Stock Movement | REMEGEN (09995) Surges Over 7% Intraday as It Releases Clinical Data for PD-1/VEGF Bispecific Antibody in NSCLC
Stock News  ·  12-11
HK Stock Movement | REMEGEN (09995) Surges Over 7% Intraday as It Releases Clinical Data for PD-1/VEGF Bispecific Antibody in NSCLC
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
Reuters  ·  12-09
BUZZ-Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating
RemeGen Co. Ltd. Held Extraordinary General Meeting
Reuters  ·  12-02
RemeGen Co. Ltd. Held Extraordinary General Meeting
BlackRock Reduces Stake in REMEGEN by 185,500 Shares at HK$81.64 Per Share
Deep News  ·  12-01
BlackRock Reduces Stake in REMEGEN by 185,500 Shares at HK$81.64 Per Share
BlackRock Reduces Stake in REMEGEN (09995) by 185,500 Shares at HK$81.64 Per Share
Stock News  ·  11-28
BlackRock Reduces Stake in REMEGEN (09995) by 185,500 Shares at HK$81.64 Per Share
HK Stock Movement | REMEGEN (09995) Rises Over 7% in Afternoon Session as Telitacicept Gains Rapid Traction and Disitamab Vedotin Shows Superior Efficacy in Combination Therapy
Stock News  ·  11-27
HK Stock Movement | REMEGEN (09995) Rises Over 7% in Afternoon Session as Telitacicept Gains Rapid Traction and Disitamab Vedotin Shows Superior Efficacy in Combination Therapy
REMEGEN (09995) Shareholder Transfers Shares from BNP Paribas to HSBC, Valued at HK$896 Million
Stock News  ·  11-27
REMEGEN (09995) Shareholder Transfers Shares from BNP Paribas to HSBC, Valued at HK$896 Million
JPMorgan Raises REMEGEN (09995) Target Price to HK$77, Upgrades to Neutral
Stock News  ·  11-04
JPMorgan Raises REMEGEN (09995) Target Price to HK$77, Upgrades to Neutral
Bank of Communications International Raises REMEGEN (09995) Target Price to HK$112, Maintains "Buy" Rating
Stock News  ·  11-04
Bank of Communications International Raises REMEGEN (09995) Target Price to HK$112, Maintains "Buy" Rating
BRIEF-Remegen Co To Purchase Wealth Management Product Of RMB400.0 Million From SPDB Yantai Branch
Reuters  ·  11-03
BRIEF-Remegen Co To Purchase Wealth Management Product Of RMB400.0 Million From SPDB Yantai Branch
REMEGEN (09995) Purchases RMB 400 Million in Wealth Management Products
Stock News  ·  11-03
REMEGEN (09995) Purchases RMB 400 Million in Wealth Management Products
RemeGen Announces RMB400 Million Wealth Management Product Purchase
Reuters  ·  11-03
RemeGen Announces RMB400 Million Wealth Management Product Purchase
RemeGen Co Ltd - to Purchase Wealth Management Product of RMB400.0 Mln From Spdb Yantai Branch
THOMSON REUTERS  ·  11-03
RemeGen Co Ltd - to Purchase Wealth Management Product of RMB400.0 Mln From Spdb Yantai Branch
RemeGen Posts Q3 Loss Despite Higher Revenue; Shares Rise 7%
MT Newswires Live  ·  10-31
RemeGen Posts Q3 Loss Despite Higher Revenue; Shares Rise 7%
Visual Guide to REMEGEN's Q3 2025 Earnings Report
Deep News  ·  10-30
Visual Guide to REMEGEN's Q3 2025 Earnings Report
REMEGEN (09995) Reports Q3 Results: Net Loss Narrows 48.6% YoY to RMB 551 Million
Stock News  ·  10-30
REMEGEN (09995) Reports Q3 Results: Net Loss Narrows 48.6% YoY to RMB 551 Million
BRIEF-Remegen Posts QTRLY Operating Revenue Rmb621.9 Million
Reuters  ·  10-30
BRIEF-Remegen Posts QTRLY Operating Revenue Rmb621.9 Million

Introduction

Company Name.
荣昌生物制药(烟台)股份有限公司
Industry:
医药制造业
Listing Date:
2022-03-31
Main Business:
　　荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
Issue price:
48.00